MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock-Private...
$49,788K
Proceeds from exercise of
series d warrants
$4,530K
Proceeds from exercise of
warrants issued-July Two...
$3,869K
Proceeds from issuance of
common stock-July Two...
$2,811K
Issuance of common stock
under employee stock...
$61K
Proceeds from employee
stock purchase plan
$12K
Proceeds from exercise of
stock options
$10K
Net cash provided by
financing activities
$40,300K
Canceled cashflow
$20,781K
Net increase
(decrease) in cash, cash...
$14,556K
Canceled cashflow
$25,744K
Repayment of debt
$20,722K
Tax withholdings
paid on behalf of...
$59K
Stock-based compensation
expense
$11,798K
Deferred revenue
$8,539K
Accrued expenses and
other current...
$3,184K
Non-cash operating lease
expense
$1,908K
Depreciation and
amortization
$900K
Loss on
extinguishment of debt
-$576K
Contract asset
-$428K
Amortization of debt discount
and issuance costs
$207K
Warrant issued for
services provided
-$152K
Modification expense related
to warrants
$15K
Proceeds from maturities
of marketable...
$26,750K
Net cash used in
operating activities
-$18,714K
Net cash (used in)
provided by investing...
-$7,030K
Canceled cashflow
$27,707K
Canceled cashflow
$26,750K
Net loss
-$40,950K
Purchases of marketable
securities
$33,692K
Accounts receivable
$2,042K
Operating lease
liabilities
-$1,909K
Accounts payable
-$1,050K
Net accretion and
amortization of investments...
$278K
Prepaid expenses and
other current assets
$192K
Purchases of property and
equipment
$88K
Back
Back
Cash Flow
source: myfinsight.com
Rani Therapeutics Holdings, Inc. (RANI)
Rani Therapeutics Holdings, Inc. (RANI)